The central role of CD4(+) T cells in the antitumor immune response

K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, H Levitsky, K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, H Levitsky

Abstract

The induction of optimal systemic antitumor immunity involves the priming of both CD4(+) and CD8(+) T cells specific for tumor-associated antigens. The role of CD4(+) T helper cells (Th) in this response has been largely attributed to providing regulatory signals required for the priming of major histocompatibility complex class I restricted CD8(+) cytolytic T lymphocytes, which are thought to serve as the dominant effector cell mediating tumor killing. However, analysis of the effector phase of tumor rejection induced by vaccination with irradiated tumor cells transduced to secrete granulocyte/macrophage colony-stimulating factor indicates a far broader role for CD4(+) T cells in orchestrating the host response to tumor. This form of immunization leads to the simultaneous induction of Th1 and Th2 responses, both of which are required for maximal systemic antitumor immunity. Cytokines produced by these CD4(+) T cells activate eosinophils as well as macrophages that produce both superoxide and nitric oxide. Both of these cell types then collaborate within the site of tumor challenge to cause its destruction.

Figures

Figure 1
Figure 1
The contribution of CD4+ and CD8+ T cell subsets to the systemic response to B16-GM-CSF vaccination. Wild-type, CD4−/−, and CD8−/− mice were injected subcutaneously in the left flank with 106 irradiated (50 Gy) B16-GM-CSF cells. Mice were challenged 2 wk later in the right flank with 105 live B16-WT cells, and examined twice weekly for the development of tumor. These data represent the results of three different experiments in which each experimental group consisted of 10 mice.
Figure 2
Figure 2
The role of cytokines in the systemic immune response to vaccination with B16-GM-CSF. (A) Mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF tumor cells and challenged 2 wk later in the opposite flank with 105 live B16-WT tumor cells. 4 d after live tumor challenge, mice were killed and total RNA was extracted from a biopsy of the tumor challenge site. At least four mice were used for each group. γ-IFN and IL-4 mRNA levels were then determined by a competitive quantitative RT-PCR assay (14). Results are shown as number of copies of γ-IFN or IL-4 message per microgram of total RNA. (B) Wild-type, γ-IFN−/−, IL-4−/−, and IL-5−/− mice were vaccinated with irradiated B16-GM-CSF cells and challenged with B16-WT cells 2 wk later in the opposite flank, as in Fig. 1. These data represent the results of three different experiments in which each experimental group consisted of 10 mice.
Figure 2
Figure 2
The role of cytokines in the systemic immune response to vaccination with B16-GM-CSF. (A) Mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF tumor cells and challenged 2 wk later in the opposite flank with 105 live B16-WT tumor cells. 4 d after live tumor challenge, mice were killed and total RNA was extracted from a biopsy of the tumor challenge site. At least four mice were used for each group. γ-IFN and IL-4 mRNA levels were then determined by a competitive quantitative RT-PCR assay (14). Results are shown as number of copies of γ-IFN or IL-4 message per microgram of total RNA. (B) Wild-type, γ-IFN−/−, IL-4−/−, and IL-5−/− mice were vaccinated with irradiated B16-GM-CSF cells and challenged with B16-WT cells 2 wk later in the opposite flank, as in Fig. 1. These data represent the results of three different experiments in which each experimental group consisted of 10 mice.
Figure 3
Figure 3
The dependence of eosinophil recruitment to the tumor challenge site on CD4+ T cells and cytokines. Mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF cells and challenged 2 wk later on the opposite flank with 105 live B16-WT cells. After 4 d, the site of live wild-type tumor challenge was removed and sections were stained with hematoxylin and eosin. (A) Wild-type, (B) CD4−/−, (C) CD8−/−, (D) IL-4−/−, (E) γ-IFN−/−, and (F) IL-5−/− C57BL/6 mice.
Figure 4
Figure 4
The role of CD4+ T cells and cytokines in priming tumor-specific CTL. Wild-type, CD4−/−, γ-IFN−/−, and IL-4−/− mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF tumor cells. After 2 wk, splenocytes were isolated and cultured for 7 d with 5 μg/ml TRP-2 peptide and 10 U/ml IL-2. On day 7, live T cells were incubated with 51Cr-labeled MC57G targets at the indicated effector to target ratios in the presence of 1 μg/ml TRP-2 peptide or irrelevant peptide. The percent peptide-specific lysis is calculated as the difference between the percent specific lysis due to the TRP-2 peptide and the percent specific lysis due to the irrelevant peptide.
Figure 5
Figure 5
Macrophages and iNOS expression at the site of wild-type tumor challenge. Mice were vaccinated with 106 irradiated (50 Gy) B16-GM-CSF tumor and challenged 2 wk later with 105 live B16-WT tumor. After 4 d, mice were killed and the live wild-type tumor challenge site was sectioned and stained for macrophages (A–F) and iNOS (G–L) (24). (A) Control for macrophage staining: no primary antibody; (B) macrophages at site of tumor challenge in wild-type mice; (C) CD4−/− mice; (D) CD8−/− mice; (E) γ-IFN−/− mice; and (F) IL-4−/− mice; (G) control for iNOS staining: no primary antibody; (H) iNOS at site of tumor challenge in wild-type mice; (I) CD4−/− mice; (J) CD8−/− mice; (K) γ-IFN−/− mice; and (L) IL-4−/− mice.

References

    1. Pardoll DM. Tumour antigens. A new look for the 1990s. Nature. 1994;369:357.
    1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725–729.
    1. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res. 1997;16:313–339.
    1. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525–531.
    1. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony–stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543.
    1. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994;179:1215–1224.
    1. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218–224.
    1. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693–1702.
    1. Inaba K, Steinman RM, Pack MW, Aya H, Inaba M, Sudo T, Wolpe S, Schuler G. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med. 1992;175:1157–1167.
    1. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow– derived cells in presenting MHC class I–restricted tumor antigens. Science. 1994;264:961–965.
    1. Lowenstein CJ, Hill SL, Lafond-Walker A, Wu J, Allen G, Landavere M, Rose NR, Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest. 1996;97:1837–1843.
    1. Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM, et al. Normal development and function of CD8+cells but markedly decreased helper cell activity in mice lacking CD4. Nature. 1991;353:180–184.
    1. Fung-Leung WP, Schilham MW, Rahemtulla A, Kundig TM, Vollenweider M, Potter J, van Ewijk W, Mak TW. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell. 1991;65:443–449.
    1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348–2357.
    1. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol. 1987;138:3688–3694.
    1. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med. 1987;166:1229–1244.
    1. Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med. 1988;168:543–558.
    1. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol. 1988;140:4245–4252.
    1. Gajewski TF, Goldwasser E, Fitch FW. Anti-proliferative effect of IFN-γ in immune regulation. II. IFN-γ inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte–macrophage colony-stimulating factor. J Immunol. 1988;141:2635–2642.
    1. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081–2095.
    1. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991;146:3444–3451.
    1. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815–3822.
    1. Locksley RM, Heinzel FP, Sadick MD, Holaday BJ, Gardner KD., Jr Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets. Ann Inst Pasteur Immunol. 1987;138:744–749.
    1. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 1988;168:1675–1684.
    1. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989;169:59–72.
    1. Street NE, Schumacher JH, Fong TA, Bass H, Fiorentino DF, Leverah JA, Mosmann TR. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol. 1990;144:1629–1639.
    1. Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. . J Exp Med. 1991;173:159–166.
    1. Heinzel FP, Sadick MD, Mutha SS, Locksley RM. Production of interferon γ, interleukin 2, interleukin 4, and interleukin 10 by CD4+lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA. 1991;88:7011–7015.
    1. Urban JF, Jr, Katona IM, Paul WE, Finkelman FD. Interleukin 4 is important in protective immunity to a gastrointestinal nematode infection in mice. Proc Natl Acad Sci USA. 1991;88:5513–5517.
    1. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science. 1993;259:1739–1742.
    1. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993;362:245–248.
    1. Campbell HD, Tucker WQ, Hort Y, Martinson ME, Mayo G, Clutterbuck EJ, Sanderson CJ, Young IG. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5) Proc Natl Acad Sci USA. 1987;84:6629–6633.
    1. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA, Jr, McIntyre BW, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol. 1992;148:1086–1092.
    1. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science. 1992;257:548–551.
    1. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713–716.
    1. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI. IL-5–deficient mice have a developmental defect in CD5+B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996;4:15–24.
    1. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte–macrophage colony-stimulating factor gene transfer. Cancer Res. 1997;57:1537–1546.
    1. Kato M, Abraham RT, Okada S, Kita H. Ligation of the β2 integrin triggers activation and degranulation of human eosinophils. Am J Respir Cell Mol Biol. 1998;18:675–686.
    1. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453–459.
    1. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480.
    1. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature. 1998;393:480–483.
    1. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+T-helper and a T-killer cell. Nature. 1998;393:474–478.
    1. Hibbs JB, Jr, Taintor RR, Chapman HA, Jr, Weinberg JB. Macrophage tumor killing: influence of the local environment. Science. 1977;197:279–282.
    1. Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med. 1989;169:1543–1555.
    1. Li LM, Kilbourn RG, Adams J, Fidler IJ. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res. 1991;51:2531–2535.
    1. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase by macrophage- derived nitric oxide. J Exp Med. 1991;174:761–767.
    1. Yim CY, Bastian NR, Smith JC, Hibbs JB, Samlowski WE. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res. 1993;53:5507–5511.
    1. Xie K, Huang S, Dong Z, Gutman M, Fidler IJ. Direct correlation between expression of endogenous inducible nitric oxide synthase and regression of M5076 reticulum cell sarcoma hepatic metastases in mice treated with liposomes containing lipopeptide CGP 31362. Cancer Res. 1995;55:3123–3131.
    1. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med. 1995;181:1333–1343.
    1. Bastian NR, Yim CY, Hibbs JB, Jr, Samlowski WE. Induction of iron-derived EPR signals in murine cancers by nitric oxide. Evidence for multiple intracellular targets. J Biol Chem. 1994;269:5127–5131.
    1. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res. 1994;54:2462–2467.
    1. Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res. 1994;54:789–793.
    1. Tanguay S, Bucana CD, Wilson MR, Fidler IJ, von Eschenbach AC, Killion JJ. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A. Cancer Res. 1994;54:5882–5888.
    1. Yim CY, McGregor JR, Kwon OD, Bastian NR, Rees M, Mori M, Hibbs JB, Jr, Samlowski WE. Nitric oxide synthesis contributes to IL-2–induced antitumor responses against intraperitoneal Meth A tumor. J Immunol. 1995;155:4382–4390.
    1. Liew FY, Millott S, Li Y, Lelchuk R, Chan WL, Ziltener H. Macrophage activation by interferon γ from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis. Eur J Immunol. 1989;19:1227–1232.
    1. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor α required as a costimulatory factor for interferon γ–induced activation. Proc Natl Acad Sci USA. 1992;89:8676–8680.
    1. Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C. Mechanism of suppression of nitric oxide synthase expression by interleukin 4 in primary mouse macrophages. J Leukocyte Biol. 1994;55:227–233.
    1. Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. The microbicidal activity of interferon γ–treated macrophages against Trypanosoma cruzi involves an l-arginine–dependent, nitrogen oxide–mediated mechanism inhibitable by interleukin 10 and transforming growth factor β. Eur J Immunol. 1992;22:2501–2506.
    1. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ–activated macrophages. J Immunol. 1992;148:1792–1796.
    1. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor β to inhibit macrophage cytotoxic activity. J Immunol. 1992;148:3578–3582.
    1. Costa JJ, Matossian K, Resnick MB, Beil WJ, Wong DT, Gordon JR, Dvorak AM, Weller PF, Galli SJ. Human eosinophils can express the cytokines tumor necrosis factor α and macrophage inflammatory protein-1 α. J Clin Invest. 1993;91:2673–2684.
    1. Beil WJ, Weller PF, Tzizik DM, Galli SJ, Dvorak AM. Ultrastructural immunogold localization of tumor necrosis factor-α to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypereosinophilic syndrome. J Histochem Cytochem. 1993;41:1611–1615.
    1. Spessotto P, Dri P, Bulla R, Zabucchi G, Patriarca P. Human eosinophil peroxidase enhances tumor necrosis factor and hydrogen peroxide release by human monocyte– derived macrophages. Eur J Immunol. 1995;25:1366–1373.
    1. Fahey TJ, III, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT, Cerami A, Sherry B. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol. 1992;148:2764–2769.
    1. Morgenstern DE, Gifford MA, Li LL, Doerschuk CM, Dinauer MC. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus. . J Exp Med. 1997;185:207–218.
    1. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985;161:1122–1134.
    1. Kern DE, Klarnet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I–restricted CTL. J Immunol. 1986;136:4303–4310.
    1. Ostrand-Rosenberg S, Roby CA, Clements VK. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol. 1991;147:2419–2422.
    1. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+tumor cells. J Immunol. 1992;149:2391–2396.
    1. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA. 1993;90:5687–5690.
    1. Wu TC, Guarnieri FG, Staveley OCKF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA. 1995;92:11671–11675.
    1. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363–1366.
    1. Nathan CF, Klebanoff SJ. Augmentation of spontaneous macrophage-mediated cytolysis by eosinophil peroxidase. J Exp Med. 1982;155:1291–1308.
    1. van der Vliet A, Eiserich JP, Halliwell B, Cross CE. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide–dependent toxicity. J Biol Chem. 1997;272:7617–7625.
    1. Green SJ, Meltzer MS, Hibbs JB, Jr, Nacy CA. Activated macrophages destroy intracellular Leishmania major amastigotes by an l-arginine–dependent killing mechanism. J Immunol. 1990;144:278–283.
    1. Liew FY, Li Y, Millott S. Tumor necrosis factor α synergizes with IFN-γ in mediating killing of Leishmania majorthrough the induction of nitric oxide. J Immunol. 1990;145:4306–4310.
    1. Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-α) in leishmaniasis. II. TNF-α–induced macrophage leishmanicidal activity is mediated by nitric oxide from l-arginine. Immunology. 1990;71:556–559.
    1. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from l-arginine. J Immunol. 1990;144:4794–4797.
    1. Liew FY, Li Y, Moss D, Parkinson C, Rogers MV, Moncada S. Resistance to Leishmania majorinfection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol. 1991;21:3009–3014.
    1. Mauel J, Ransijn A, Buchmuller-Rouiller Y. Killing of Leishmania parasites in activated murine macrophages is based on an l-arginine–dependent process that produces nitrogen derivatives. J Leukocyte Biol. 1991;49:73–82.
    1. Evans TG, Thai L, Granger DL, Hibbs JB. Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis. J Immunol. 1993;151:907–915.
    1. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, Liew FY, Moncada S. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. . Eur J Immunol. 1994;24:672–676.
    1. Stenger S, Thuring H, Rollinghoff M, Bogdan C. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. . J Exp Med. 1994;180:783–793.
    1. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature. 1995;375:408–411.
    1. Morris L, Troutt AB, McLeod KS, Kelso A, Handman E, Aebischer T. Interleukin-4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis. Infect Immun. 1993;61:3459–3465.
    1. Liew FY, Li Y, Severn A, Millott S, Schmidt J, Salter M, Moncada S. A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol. 1991;21:2489–2494.
    1. al-Ramadi BK, Meissler JJ, Jr, Huang D, Eisenstein TK. Immunosuppression induced by nitric oxide and its inhibition by interleukin-4. Eur J Immunol. 1992;22:2249–2254.
    1. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J Immunol. 1993;151:1224–1234.
    1. Urban JF, Jr, Madden KB, Svetic A, Cheever A, Trotta PP, Gause WC, Katona IM, Finkelman FD. The importance of Th2 cytokines in protective immunity to nematodes. Immunol Rev. 1992;127:205–220.
    1. Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti–IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. . J Immunol. 1989;143:266–274.
    1. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon γ–deficient mice infected with Leishmania major. . J Exp Med. 1994;179:1367–1371.
    1. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell–dependent, interferon γ–independent mechanism. J Exp Med. 1990;171:115–127.
    1. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, Maliszewski CR. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine– anti-cytokine antibody complexes. J Immunol. 1993;151:1235–1244.
    1. Finkelman FD, Madden KB, Cheever AW, Katona IM, Morris SC, Gately MK, Hubbard BR, Gause WC, Urban JF., Jr Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med. 1994;179:1563–1572.
    1. Chatelain R, Varkila K, Coffman RL. IL-4 induces a Th2 response in Leishmania major–infected mice. J Immunol. 1992;148:1182–1187.
    1. Reed SG, Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol. 1993;5:524–531.
    1. Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+T cells during initiation of infection. J Exp Med. 1994;179:447–456.
    1. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with granulocyte–macrophage colony-stimulating factor–transduced, but not B7-1–transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol. 1996;156:3858–3865.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться